Aruba Science Wire
SEE OTHER BRANDS

Your best source on science and technology news from Aruba

Aruba Science Wire: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Aruba Science Wire.

Press releases published on June 25, 2025

Basecamp Research Announces Malawi Biodiscovery Partnership in Series of New Collaborations Across Three Continents at UK Government Nature Action Event

Basecamp Research Announces Malawi Biodiscovery Partnership in Series of New Collaborations Across Three Continents at UK Government Nature Action Event

Partnerships with Malawi, Hungary, and other new partners will rapidly expand BaseData, the largest biological protein database designed specifically for training generative AI foundation models to improve drug discovery and planetary health. …

DIMERx Awarded Up to $15M by NIDA Under NIH HEAL Initiative® to Advance DMX-101 as a Non-Addictive Oral Therapy for Chronic Pain

DIMERx Awarded Up to $15M by NIDA Under NIH HEAL Initiative® to Advance DMX-101 as a Non-Addictive Oral Therapy for Chronic Pain

SAN FRANCISCO, June 25, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage biopharmaceutical company entering growth phase, today announced it has been awarded a UG3/UH3 cooperative agreement (UG3DA061645) for up to $15 million from the National Institute …

For mining novices: PBKMiner launches free BTC, ETH, DOGE and XRP cloud mining services

For mining novices: PBKMiner launches free BTC, ETH, DOGE and XRP cloud mining services

London, UK, June 25, 2025 (GLOBE NEWSWIRE) -- The global cryptocurrency market has entered a new era of acceptance and legitimacy following the US government’s landmark decision to establish a strategic Bitcoin reserve in March 2025. Riding on this …

Gero Launches ProtoBind-Diff, a Structure-Free AI Foundation Model for Targeted Small Molecule Discovery

Gero Launches ProtoBind-Diff, a Structure-Free AI Foundation Model for Targeted Small Molecule Discovery

ProtoBind-Diff generates drug-like molecules for specific protein targets using only their amino acid sequences—no 3D structures required. The model performs competitively with leading structure-based tools in predicting binding strength, while also …

XRP Mining Launches New Cloud Mining App for Global Users

XRP Mining Launches New Cloud Mining App for Global Users

San Francisco, California, June 25, 2025 (GLOBE NEWSWIRE) -- With the rapid development of the digital financial world, cryptocurrency has become a global focus. However, it is difficult for ordinary people to succeed in this field. Traditional …

BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System

BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System

SUNNYVALE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office …

Report: 1 in 2 Employees Have Excessive Privileged Access—CloudEagle.ai Survey Warns of Escalating Insider Risk due to AI and SaaS Sprawl

Report: 1 in 2 Employees Have Excessive Privileged Access—CloudEagle.ai Survey Warns of Escalating Insider Risk due to AI and SaaS Sprawl

PALO ALTO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- A new report from CloudEagle.ai, the AI-powered SaaS management and governance platform, reveals that 60% of enterprise SaaS and AI applications now operate outside IT's visibility. This surge in “ …

ImmuCell Embarks on CEO Succession Planning Process

ImmuCell Embarks on CEO Succession Planning Process

PORTLAND, Maine, June 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …

OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting

OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting

MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment …

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it …

BIO-key Joins ISMS Forum to Advance Cybersecurity and Identity Management Best Practices in Spain

BIO-key Joins ISMS Forum to Advance Cybersecurity and Identity Management Best Practices in Spain

MADRID and HOLMDEL, N.J., June 25, 2025 (GLOBE NEWSWIRE) -- BIO-key International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication solutions, today announced that it has joined ISMS Forum, Spain’s …

Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment

Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment

CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: …

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results

Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA) Interim Phase 1 data show children with SMA previously treated with gene therapy …

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)

- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the …

Verano Unveils Bodega-Style Dispensary Experience at Zen Leaf Cave Creek in Phoenix

Verano Unveils Bodega-Style Dispensary Experience at Zen Leaf Cave Creek in Phoenix

Flipping the script on the traditional dispensary format, the new bodega-style shopping experience offers customers the freedom to browse and select their favorite items directly from shelves featuring one of the largest assortments of directly accessible …

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer

Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll children with high grade glioma and ependymoma HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ( …

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2025 ( …

Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer

Oncotelic Therapeutics Announces Publication of Landmark Study on TGFB2 Gene Methylation as a Positive Prognostic Marker in Pancreatic Cancer

AGOURA HILLS, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC) ("Oncotelic" or the "Company"), a clinical-stage biopharmaceutical company focused on RNA-based therapeutics, today announced the publication of a peer- …

MetasTx Secures NCI Grant to Enable the Advancement of Dual-Track Strategy Against Metastatic Prostate Cancer

MetasTx Secures NCI Grant to Enable the Advancement of Dual-Track Strategy Against Metastatic Prostate Cancer

PITTSBURGH, June 25, 2025 (GLOBE NEWSWIRE) -- MetasTx, LLC, a biotechnology company focused on preventing the metastasis of solid tumor cancers – like prostate, breast and skin, announced today it has received a Small Business Innovation Research (SBIR) …

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474 In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service